Moffitt logo

Clinical Trials Search

Clinical Trial 19635

Cancer Type: Malignant Hematology

Study Type: Treatment
Phase of Study: Phase I/II

  • Rami Komrokji

Call 813-745-6100
or 1-800-679-0775

Study Title

A Phase 1b/2 Study Evaluating the Safety and Efficacy of Intravenous LB-100 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) who had Disease Progression or are Intolerant to Prior Therapy



Primary Objective (Phase1b): 1.To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of LB-100 as determined by dose-limiting toxicities (DLTs) Primary Objective (Phase 2): 2.To estimate overall best response rates of LB-100 using standard international working group (IWG) 2006 response criteria Secondary Objectives (Phase 1b and 2): 3.To characterize the plasma pharmacokinetics (PK) of LB-100 (Phase 1b only) 4.To evaluate the effect of LB-100 on the hematologic and cytogenetic response in patients with deletion 5q (del(5q)) MDS 5.To estimate the duration of response 6.To estimate the time to AML transformation of subjects on LB-100 7.To characterize in vivo LB-100 target inhibition 8.To characterize the effect of LB-100 treatment on erythropoietin signaling 9.To determine whether recurrent genetic mutations are predictive of LB-100 response

Inclusion Criteria

  • Participant has signed the Informed Consent Form (ICF) and is able to comply with protocol requirements.
  • Participant has adequate organ function as defined by laboratory values per protocol.
  • Age ≥18 years at the time of signing the informed consent form.
  • Documented diagnosis of MDS or MDS/myeloproliferative neoplasm (MPN) by World Health Organization (WHO) criteria that require treatment due to cytopenias and meet the International Prognostic Scoring System (IPSS) criteria for low or int-1 risk.
  • For non-del(5q) participants, failed prior treatment with at least 2 cycles started of azacitidine or decitabine or lenalidomide defined as no response to treatment, loss of response at any time point while on treatment or within 6 months of treatment discontinuation, or progressive disease/intolerance to therapy.
  • For del(5q) participants, failed prior treatment with at least 2 cycles started of lenalidomide defined as no response to treatment, loss of response at any time point, or progressive disease/intolerance to therapy.
  • An Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence; tubal ligation, partner's vasectomy) prior to Cycle 1 Day 1 (C1D1) and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

  • Exclusion Criteria

  • Known history of HIV infection (testing not mandatory).
  • Any of the following cardiac abnormalities: symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to enrollment, unstable angina pectoris as designated by the treating physician, serious uncontrolled cardiac arrhythmia as designated by the treating physician, QTcF (Fridericia's correction formula) ≥ 450 msec.
  • Concomitant malignancies or previous malignancies with less than a 1-year disease free interval at the time of enrollment. Participants with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (i.e. cervix) may enroll irrespective of the time of diagnosis.
  • Use of chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 14 days of the first day of study drug treatment.
  • No concurrent use of erythroid stimulating agents, Granulocyte-colony stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF) is allowed during study except in cases of febrile neutropenia where G-CSF can be used for short term. Growth factors must be stopped two weeks prior to study.
  • Pregnant women are excluded from this study because LB-100 has not been studied in pregnant subjects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with LB-100, breastfeeding should be discontinued if the mother is treated with LB-100.